A randomized, dose-response, multicenter phase II study of radium-223 chloride for the palliation of painful bone metastases in patients with castration-resistant prostate cancer. (Q37985149)
Jump to navigation
Jump to search
scientific article published on 15 February 2012
| Language | Label | Description | Also known as |
|---|---|---|---|
| English | A randomized, dose-response, multicenter phase II study of radium-223 chloride for the palliation of painful bone metastases in patients with castration-resistant prostate cancer. |
scientific article published on 15 February 2012 |
Statements
A randomized, dose-response, multicenter phase II study of radium-223 chloride for the palliation of painful bone metastases in patients with castration-resistant prostate cancer (English)
S Nilsson
P Strang
A K Aksnes
L Franzèn
P Olivier
A Pecking
J Staffurth
S Vasanthan
15 February 2012